Engflag

Cardace Forte

Quick links to important sections

Cardace Forte

Cardace Forte_EN

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Diuretic, Hypotensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardace Forte

Quick Facts

Property Description
Active Ingredients Ramipril and Hydrochlorothiazide
Form Oral Tablet
Pharmacological Class ACE Inhibitor Plus Diuretic (Antihypertensive)
Common Use Management of High Blood Pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Cardace Forte?

Cardace Forte is a prescription-only, synthetic fixed-dose combination antihypertensive agent. This medicine belongs to the Angiotensin-Converting Enzyme (ACE) Inhibitor Plus Diuretic pharmacological class, signifying its dual-mechanism approach to managing elevated blood pressure (hypertension). The combination is designed to simplify therapeutic regimens for adults who require the efficacy of combined treatment, a standard strategy for treating high blood pressure. The Ramipril component is clinically recognized for its long-term benefits in cardiovascular risk reduction, distinguishing this specific class combination.

Composition and Form: Ramipril and Hydrochlorothiazide

The composition of Cardace Forte relies on two distinct active synthetic ingredients: the ACE inhibitor Ramipril and the thiazide diuretic Hydrochlorothiazide. Ramipril works by inducing vasodilatation (vessel relaxation) through inhibition of the ACE enzyme. Concurrently, Hydrochlorothiazide acts as the diuretic component, increasing the kidney's excretion of Sodium and water to reduce the circulating fluid volume. The simultaneous administration of these two components provides demonstrably enhanced antihypertensive effects in patients. The medication is formulated exclusively as an oral tablet for administration via the oral route.

Cardace Forte's General Purpose in Blood Pressure Management

The general purpose of Cardace Forte is to provide dual-pathway control over hypertension by simultaneously addressing vascular tension and fluid volume. By combining the effects of vessel relaxation and fluid removal, the medication generates a synergistic action that lowers the overall circulatory load. This dual therapeutic action effectively decreases the pressure exerted on the arterial walls, which is the foundational goal of long-term hypertension management. This strategic combination of drug classes is supported by global treatment guidelines as an effective strategy for managing established hypertension.

Regulatory References

  1. MedlinePlus: High Blood Pressure

What side effects are possible with Cardace Forte?

Possible side effects and safety information

The official safety profile for the Ramipril/Hydrochlorothiazide combination is structured around adverse reactions categorized by frequency and the physiological systems affected. This information is derived exclusively from regulatory documents and guides the understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by regulatory bodies based on their incidence rates reported in clinical data and post-marketing surveillance. Common reactions (occurring in 1% to 10% of patients) typically include headache, dizziness, fatigue, and a dry, non-productive cough (a known ACE inhibitor class effect). Reactions classified as Uncommon (0.1% to 1%) may involve low blood pressure (hypotension), gastrointestinal issues such as nausea or diarrhea, and electrolyte changes.

Serious Adverse Reactions and Systemic Risks

Regulatory documentation highlights serious and clinically significant risks. The most critical is Angioedema (severe swelling of the face, tongue, or larynx), which is potentially life-threatening. Serious systemic risks also include Fetal Toxicity; the medicine is Contraindicated in the second and third trimesters of pregnancy due to the risk of injury or death to the fetus. The label also notes rare occurrences of severe blood disorders (e.g., neutropenia) and hepatic failure.

Population-Specific and Duration-Related Safety

Specific safety considerations apply to certain patient populations and exposure patterns. The medicine is Contraindicated in patients with severe renal impairment or severe hepatic impairment. Furthermore, Non-Melanoma Skin Cancer is officially linked to increasing cumulative dose and long-term exposure to the Hydrochlorothiazide component. Hypotension is noted as being more likely to occur following the initiation of therapy or a dose increase.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

Official regulatory documents define Cardace Forte overdose primarily through the effects of severe blood pressure collapse and critical fluid and electrolyte disruption. The most common manifestations documented in regulatory labeling include excessive hypotension (profound drop in blood pressure), tachycardia, and signs of severe electrolyte imbalance such as hyponatremia (low sodium) and hypokalemia (low potassium). Other systemic symptoms documented are drowsiness, confusion, and oliguria (decreased urine output).

The most serious, life-threatening outcome documented is the risk of fatal angioedema of the glottis or larynx, which can cause airway obstruction. Regulatory guidance mandates that patients or caregivers seek immediate medical attention or contact emergency services if symptoms such as swelling of the face, tongue, or throat, or profound dizziness occur.

Overdose Management

Management of a suspected overdose is defined by regulatory bodies as symptomatic and supportive treatment. No specific antidote is known. Measures for supportive care include administering an intravenous infusion of saline to address volume depletion and hypotension, and replacement of electrolytes. For angioedema that threatens the airway, administration of subcutaneous epinephrine is a specific emergency procedure described in prescribing information. Patients are required to undergo close monitoring of vital signs, serum electrolytes, and renal function until clinical stability is achieved. Individuals who are already salt- or volume-depleted are noted to be at increased risk for symptomatic hypotension.

Therapeutic Uses of Cardace Forte

What Cardace Forte Treats: Main Uses and Benefits

Cardace Forte is commonly used for the sustained management of high blood pressure (hypertension). This fixed-dose combination is considered relevant for patients who require additional symptomatic support beyond a single medication. The therapeutic domains include addressing symptoms related to heightened physiological activity and systemic imbalance.

Therapeutic Focus and Benefits

This treatment strategy helps address the sustained elevation, contributing to improved comfort during periods of heightened symptoms. The long-term application includes supportive benefits, as consistent therapy is relevant for easing the high physiological stress associated with chronic pressure, thereby helping with easing the noticeable physiological strain associated with chronic high pressure and may be part of symptomatic management applied in conditions linked to organ-specific functional stress. For individuals who require the concurrent action of two different drug classes, using a combination product may assist with maintaining functional stability by supporting adherence to the long-term treatment plan.

Quick Facts

Quick Fact Description
Support for Systemic Imbalance Provides supportive relief when symptoms interfere with routine activities.
Clinical Scenarios Often used as long-term maintenance therapy when symptoms become more noticeable.
Patient Benefit Contributes to easing the overall symptom load associated with chronic high pressure and supports patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory information specifies the populations who are eligible, restricted, or prohibited from using the fixed-dose combination Cardace Forte (Ramipril/Hydrochlorothiazide).

Populations Prohibited from Use (Contraindicated)

The medicine is strictly contraindicated for several groups based on organ function, clinical history, and physiological status:

  • History of Angioedema or Hypersensitivity: Patients who have experienced angioedema (swelling) or are hypersensitive to any ACE inhibitor, sulfonamide-derived drug, or thiazide diuretic component must not use this medicine.
  • Severe Organ Impairment: Contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min) or severe hepatic impairment (severe liver dysfunction).
  • Pregnancy and Lactation: Use is contraindicated during the second and third trimesters of pregnancy and throughout breastfeeding.
  • Renal Structure: Patients with bilateral renal artery stenosis or stenosis in a single functioning kidney are prohibited from use.
  • Concomitant Therapy: Contraindicated with concurrent use of sacubitril/valsartan and with aliskiren in patients with diabetes or renal impairment.

Restricted or Non-Recommended Use

  • Pediatric Population: Use is not recommended in children and adolescents under 18 years due to insufficient data on safety and efficacy.
  • Moderate Organ Impairment: Patients with moderate renal or hepatic impairment may use the medicine only under close medical supervision and often with reduced dosing restrictions.
  • Elderly Patients: Treatment initiation may require lower doses and a more gradual titration schedule.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cardace Forte (Ramipril/Hydrochlorothiazide) identifies specific substance combinations and co-administered agents that may alter the drug's effects, as documented in government regulatory information.

Interaction Domains and Constraints

Constraint Type Interacting Substance/Class Regulatory Requirement
Absolute Contraindication Sacubitril/Valsartan Prohibited; requires a mandatory 36-hour washout period.
Conditional Contraindication Aliskiren, ARBs Prohibited in patients with Diabetes Mellitus or Renal Impairment.
Pharmacodynamic Risk Potassium-sparing diuretics, NSAIDs, Alcohol Heightened risk of Hyperkalemia or Reduced Antihypertensive Effect.
Exposure Modification Lithium, Bile acid-binding resins Lithium clearance is reduced. Resins require 4 to 6 hours separation to prevent reduced absorption.
Procedural Restriction Extracorporeal treatments Prohibited due to the risk of severe anaphylactoid reactions.

Official Interaction Statements

The combination with Lithium is documented to reduce Lithium's renal clearance, resulting in increased exposure and potential toxicity. Co-administration with Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may result in a reduced blood pressure-lowering effect and a risk of changes to renal function. Concurrent use with agents that elevate potassium (like supplements) increases the risk of Hyperkalemia. These official classifications establish strict constraints and specific co-administration conditions as defined by regulatory authorities.

Mechanism of Action

Cardace Forte (ramipril) is an angiotensin-converting enzyme (ACE) inhibitor. Following its conversion to the active metabolite ramiprilat, the compound binds reversibly to the active site of the ACE enzyme, a component of the renin-angiotensin-aldosterone system (RAAS). This interaction competitively inhibits the cleavage of the decapeptide Angiotensin I into the potent vasoconstrictor Angiotensin II. The resulting decrease in Angiotensin II concentration leads to a reduction in systemic vascular resistance, primarily through diminished peripheral vasoconstriction. Additionally, the decrease in Angiotensin II reduces the synthesis and secretion of aldosterone, contributing to a reduction in sodium and fluid retention and a subsequent decrease in plasma volume. Furthermore, the action of Cardace Forte mitigates the proliferative signaling cascades mediated by Angiotensin II, thereby modulating cellular remodeling processes within cardiac and vascular tissues.

Dosage and Administration Information

How to Use Cardace Forte: Official Administration Guidelines

Cardace Forte is a prescription medicine formulated as a fixed-dose combination of Ramipril and Hydrochlorothiazide (HCTZ), intended for the management of chronic high blood pressure. Usage must adhere strictly to the procedural guidelines established by regulatory authorities.

Administration Scope

Feature Guideline
Route of administration Oral administration only.
Dosing schedule Used as a maintenance regimen; not for initiating therapy. Dosing follows titration with individual components. The maximum daily dose is typically restricted (e.g., up to 10 mg Ramipril / 25 mg HCTZ).
Frequency and Timing Typically administered once daily, preferably in the morning.
Timing in relation to meals Can be taken with or without food.
Preparation requirements The tablet must be swallowed whole with liquid and should not be chewed or crushed.

Usage Patterns and Special Conditions

Treatment is intended for long-term maintenance. If a dosage adjustment is required during the course of therapy, official prescribing information often advises switching back to the individual components for precise dose titration.

Population-Specific Rules:

  • Severe Renal Impairment: The fixed combination is generally not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min).
  • Older Adults: Lower initial doses and more gradual dose titration are advised for elderly patients due to potentially increased sensitivity.

If a dose is missed, patients should skip the missed dose if it is near the time for the next scheduled dose, and must not double the dose to compensate. These guidelines define the standardized use of the medication as documented in official regulatory materials.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardace Forte

Evidence for Use in High Blood Pressure

Short-term Randomized Controlled Trials (RCTs) were conducted, primarily to explore the use of the fixed-dose combination in adults with Essential Hypertension, including those with Stage 1 or Stage 2 blood pressure readings. These studies were designed to compare the combination pill against using the individual component medicines, ramipril or hydrochlorothiazide, alone. Findings indicate that the combination was associated with different patterns of blood pressure change compared to the patterns observed when patients received either of the two component medicines alone. Studies reported patterns showing whether patients reached pre-defined blood pressure goals when studied using the combination regimen. However, the duration of many of these dedicated initial research studies was short.

Evaluation of Fixed-Dose Combination Therapy

A significant portion of the evidence landscape was used in research exploring how a fixed-dose combination (FDC) compares to a multi-pill regimen (taking the same dose of the two medicines as separate pills). Research describes patterns showing that the use of a single-pill combination was associated with different rates of medication adherence and persistence over time compared to a multi-pill regimen. In some large, real-world observational studies, adherence patterns were observed in studies evaluating composite clinical outcomes. While the studies show an association, the direct causal relationship between the FDC pill and the observed patterns in clinical events remains unclear based on current evidence.

Long-Term Evidence and Follow-up

Long-term follow-up evidence primarily exists in observational settings, which assessed patient data over several years. While some long-term observational data show patterns related to composite clinical outcomes, the findings were mixed, and evidence quality varies across studies. Dedicated, multi-year randomized trials assessing the long-term effects of this specific FDC beyond initial blood pressure changes are limited.

Evidence in Specific Patient Groups

The medicine was evaluated in a wide range of adults with hypertension, including cohorts of older adults and those with specific comorbidities. Data for certain groups remain insufficient. There is limited information available on the safety or effectiveness of the fixed combination in children (under 18 years of age). Similarly, data for certain geriatric subgroups are less extensive, and regulatory reports indicate limited clinical experience with the fixed combination in these populations.

Research Gaps and Areas of Uncertainty

As noted, the most rigorous randomized trials focus on blood pressure reduction and are often short-term, meaning evidence for long-term outcomes is limited within this study type. Regulatory summaries have noted limited trial data regarding established steps for dose adjustment or titration using the fixed-dose combination product itself. Research provides context but not individual predictions. Findings describe group patterns observed in the studies and do not determine whether an individual will respond similarly.

Key Studies & References

  1. WHO/ISH Global Hypertension Practice Guidelines: Evidence for Combination Therapy in Hypertension Management

Frequently Asked Questions (FAQ)

Common questions about Cardace Forte (FAQ)

Q: What is the mechanism of action of Cardace Forte?

Cardace Forte is a combination medicine that works in two ways, according to official regulatory documents. The Ramipril component works as an ACE inhibitor, which aids in blood pressure reduction by inhibiting the formation of Angiotensin II. The Hydrochlorothiazide component is a diuretic (water pill) that helps the kidneys excrete excess sodium and water from the body, thereby reducing fluid volume.

Q: Can I stop taking Cardace Forte if my blood pressure is normal?

Official prescribing information indicates that Cardace Forte is intended for the long-term management of chronic high blood pressure. Regulatory documents do not provide specific guidance on stopping the medication after blood pressure has been controlled. Changes to a prescribed maintenance therapy regimen should always be made in consultation with a healthcare professional.

Q: Is Cardace Forte safe to take during pregnancy or breastfeeding?

Official regulatory warnings state that Cardace Forte is contraindicated (should not be used) during the second and third trimesters of pregnancy due to the known risk of injury or death to the fetus. Official regulatory information generally advises against its use during the first trimester, and it is also contraindicated throughout the entire breastfeeding period.

Q: How long does it take for Cardace Forte to start working?

According to the official product information, the initial blood pressure-lowering effect from the Ramipril component typically begins within 1 to 2 hours of taking a dose. The peak effect is usually seen within 3 to 6 hours, though the complete desired therapeutic effect for treating chronic high blood pressure may take a few weeks to develop.

Q: Are there any known long-term side effects or risks associated with Cardace Forte?

Regulatory documents highlight specific risks associated with long-term use. The Hydrochlorothiazide component has been associated with an increased risk of a serious skin condition called Non-Melanoma Skin Cancer with increasing cumulative dose and long-term exposure. Other long-term risks mentioned in official safety profiles include the possibility of electrolyte imbalances and rare serious systemic effects.

Q: Does Cardace Forte have any effect on my cholesterol levels?

Official clinical trial data and adverse reaction profiles note that some patients may experience metabolic disturbances. Official safety profiles for the Hydrochlorothiazide component indicate that it has been associated with increases in blood lipids, including cholesterol and triglycerides, in some patients.

Q: Is Cardace Forte a blood thinner?

No. Cardace Forte is classified by regulatory bodies as an ACE inhibitor and a diuretic, which are medicines used to treat high blood pressure. Its action is to help lower blood pressure by promoting the relaxation of blood vessels and reducing fluid volume, not by preventing blood clot formation.

How should Cardace Forte be stored and disposed of?

The storage and disposal of Cardace Forte (ramipril/hydrochlorothiazide) must strictly follow official regulatory guidelines to maintain product quality and ensure safety.

Requirement Condition
Storage Temperature Store at Controlled Room Temperature (typically 20 C to 25 C).
Environmental Protection Protect the tablets from moisture, excessive heat, and freezing [1.2, 3.3].
Packaging Rules Keep the medicine in the original container and ensure the container is tightly closed [3.3].
Child Safety Keep out of the sight and reach of children [3.3].
Disposal Do not flush unused or expired medicine down a toilet or pour into a drain. Consult a healthcare professional or use an official drug take-back program for proper disposal [NIH/MedlinePlus].

The official storage conditions are mandated to safeguard the stability of the active ingredients, requiring the product to be stored within a specific temperature range and shielded from moisture and light. Proper disposal methods are explicitly defined by regulators, prioritizing safe collection options to prevent environmental contamination and accidental exposure to unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEstonia

Equivalent of Cardace Forte found in:

A-Z Index: